
Sign up to save your podcasts
Or


Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
By Wondery4.6
1254312,543 ratings
Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

10,446 Listeners

30,215 Listeners

775 Listeners

467 Listeners

3,994 Listeners

19,234 Listeners

4,162 Listeners

19,139 Listeners

2,150 Listeners

2,947 Listeners

3,044 Listeners

22,951 Listeners

904 Listeners

1,466 Listeners

7,772 Listeners

256 Listeners

2,512 Listeners

251 Listeners

2,150 Listeners

7,401 Listeners

851 Listeners

1,526 Listeners

237 Listeners

596 Listeners

429 Listeners

66 Listeners

536 Listeners

871 Listeners

208 Listeners